In GALAXIES, there was a “clinically meaningful” reduction at every dose of the combination tested compared to monotherapy with Jemperli or MSD’s PD-1 inhibitor Keytruda (pembrolizumab ...

Leading Nousom’s pipeline is off-the-shelf vaccine NOUS-209, which targets 209 shared neoantigens and is being tested alongside MSD’s checkpoint inhibitor Keytruda (pembrolizumab) in a phase 2 ...

Alliance Global Partners lowered the firm’s price target on PDS Biotechnology (PDSB) to $4.50 from $7 and keeps a Buy rating on the ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

SpiritMedia.US, a leading international book publishing and marketing company, celebrates the release of The Pyramid Principle by John Vallely with Paul Weissenstein on Tuesday9, 2024. The book shares ...

Avi Kapoor Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo JMP Securities initiates coverage on Summit Therapeutics, citing ...